Advertisement

Journal of Endocrinological Investigation

, Volume 27, Issue 4, pp 311–317 | Cite as

Galectin-3: Presurgical marker of thyroid follicular epithelial cell-derived carcinomas

  • E. Saggiorato
  • S. Aversa
  • D. Deandreis
  • F. Arecco
  • A. Mussa
  • B. Puligheddu
  • S. Cappia
  • S. Conticello
  • M. Papotti
  • F. Orlandi
Article

Abstract

Preoperative follicular lesion characterisation represents an unsolved diagnostic problem in thyroid nodular disease. Although fine-needle aspiration biopsy is the most reliable preoperative diagnostic procedure, it shows inherent limitations in differentiating adenoma from follicular carcinoma and, sometimes, follicular variants of papillary carcinoma. Galectin-3 cytoplasmic neoexpression has been proposed as a peculiar feature of thyroid malignant cells, easily detectable in cytological and histological samples. The aim of this study was to re-evaluate the galectin-3 expression in a large sample of thyroid lesions using an immunohistocytochemical biotin-free detection system and a specific anti-human-galectin-3 monoclonal antibody in order to avoid the interference of technical factors, a cause of conflicting results recently reported by some authors. We analysed galectin-3 expression of 39 follicular carcinomas, 26 papillary carcinomas, and 105 adenomas in both cell-block samples and their histological counterparts. All cell-block and histological papillary carcinoma samples showed high levels of galectin-3 immunoreactivity. Thirty-four follicular carcinomas were positive, whereas 5 were negative in cell-blocks but positive in their histological counterparts. Twelve out of 105 adenomas expressed galectin-3 in cell-blocks and histological samples. The diagnostic accuracy of preoperative galectin-3 evaluation in adenomas vs follicular carcinomas was 90.0%. Galectin-3 expression was also investigated in 22 minimally-invasive follicular carcinomas. All of them showed galectin-3 immunoreactivity in both cytological and histo-logical specimens with the exception of two cases, where galectin-3 positivity was observed only in the surgical material. The routine correct use of galectin-3, by increasing the diagnostic accuracy of conventional cytology, improves the management of thyroid nodules and can lead to a sensitive reduction of useless thyroid surgeries.

Key-words

Galectin-3 lectins thyroid neoplasms thyroid diseases fine-needle aspiration biopsy 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Mazzaferri EL. Management of a solitary thyroid nodule. N Engl J Med 1993, 328: 553–9.PubMedCrossRefGoogle Scholar
  2. 2.
    Hegedus L, Bonnema SJ, Bennedbaek FN. Management of simple nodular goiter: current status and future perspectives. Endocr Rev 2003, 24: 102–32.PubMedCrossRefGoogle Scholar
  3. 3.
    Hamming JF, Goslings BM, van Steenis GJ, et al. The value of fine-needle aspiration biopsy in patients with nodular thyroid disease divided into groups of suspicion of malignant neoplasms on clinical grounds. Arch Intern Med 1990, 150: 113–6.PubMedCrossRefGoogle Scholar
  4. 4.
    Caraci P, Aversa S, Mussa A, Pancani G, Ondolo C, Conticello S. Role of fine-needle aspiration biopsy and frozen-section evaluation in the surgical management of thyroid nodules. Br J Surg 2002, 89: 797–801.PubMedCrossRefGoogle Scholar
  5. 5.
    Caraway NP, Sneige N, Samaan NA. Diagnostic pitfalls in thyroid fine-needle aspiration: a review of 394 cases. Diagn Cytopathol 1993, 9: 345–50.PubMedCrossRefGoogle Scholar
  6. 6.
    Rosai J, Carcangiu ML, De Lellis RA. Tumors of the thyroid gland. In: Ellis GL and Auclair PL eds. Atlas of tumor pathology. Washington DC: Armed Forces Institute of Pathology. 1992, 49–62.Google Scholar
  7. 7.
    Schlumberger M, Pacini F. Thyroid tumors. Paris: Édtions Nucléon. 1999, 33–42.Google Scholar
  8. 8.
    Saggiorato E, Cappia S, De Giuli P, et al. Galectin-3 as a presurgical immunocytodiagnostic marker of minimally invasive follicular thyroid carcinoma. J Clin Endocrinol Metab 2001, 86: 5152–8.PubMedCrossRefGoogle Scholar
  9. 9.
    Ogawa Y, Kato Y, Ikeda K, et al. The value of ultrasound-guided fine-needle aspiration cytology for thyroid nodules: an assessment of its diagnostic potential and pitfalls. Surg Today 2001, 31: 97–101.PubMedCrossRefGoogle Scholar
  10. 10.
    Papini E, Guglielmi R, Bianchini A, et al. Risk of malignancy in nonpalpable thyroid nodules: predictive value of ultrasound and color-Doppler features. J Clin Endocrinol Metab 2002, 87: 1941–6.PubMedCrossRefGoogle Scholar
  11. 11.
    Harms H, Hofmann M, Ruschenburg I. Fine needle aspiration of the thyroid: can an image processing system improve differentiation? Anal Quant Cytol Histol 2002, 24: 147–53.PubMedGoogle Scholar
  12. 12.
    Tangpricha V, Chen BJ, Swan NC, et al. Twenty-one-gauge needles provide more cellular samples than twenty-five-gauge needles in fine-needle aspiration biopsy of the thyroid but may not provide increased diagnostic accuracy. Thyroid 2001, 11: 973–6.PubMedCrossRefGoogle Scholar
  13. 13.
    Yang GC, Liebeskind D, Messina AV. Should cytopathologists stop reporting follicular neoplasms on fine-needle aspiration of the thyroid? Cancer 2003, 99: 69–74.PubMedCrossRefGoogle Scholar
  14. 14.
    Serini G, Trusolino L, Saggiorato E, et al. Changes in integrin and E-cadherin expression in neoplastic versus normal thyroid tissue. J Natl Cancer Inst 1996, 88: 442–9.PubMedCrossRefGoogle Scholar
  15. 15.
    Haugen BR, Woodmansee WW, McDermott MT. Towards improving the utility of fine-needle aspiration biopsy for the diagnosis of thyroid tumors. Clin Endocrinol (Oxf) 2002, 56: 281–90.CrossRefGoogle Scholar
  16. 16.
    Raphael SJ. The meanings of markers: ancillary techniques in diagnosis of thyroid neoplasia. Endocr Pathol 2002, 13: 301–11.PubMedGoogle Scholar
  17. 17.
    Liou MJ, Chan EC, Lin JD, Liu FH, Chao TC. Human telomerase reverse transcriptase (hTERT) gene expression in FNA samples from thyroid neoplasms. Cancer Lett 2003, 191: 223–7.PubMedCrossRefGoogle Scholar
  18. 18.
    Saji M, Xydas S, Westra WH, et al. Human telomerase reverse transcriptase (hTERT) gene expression in thyroid neoplasms. Clin Cancer Res 1999, 5: 1483–9.PubMedGoogle Scholar
  19. 19.
    Chiappetta G, Tallini G, De Biasio MC, et al. Detection of high mobility group I HMGI(Y) protein in the diagnosis of thyroid tumors: HMGI(Y) expression represents a potential diagnostic indicator of carcinoma. Cancer Res 1998, 58: 4193–8.PubMedGoogle Scholar
  20. 20.
    van Hoeven KH, Kovatich AJ, Miettinen M. Immunocy-tochemical evaluation of HBME-1, CA 19-9, and CD-15 (Leu-M1) in fine-needle aspirates of thyroid nodules. Diagn Cytopathol 1998, 18: 93–7.PubMedCrossRefGoogle Scholar
  21. 21.
    Sack MJ, Astengo-Osuna C, Lin BT, Battifora H, LiVolsi VA. HBME-1 immunostaining in thyroid fine-needle aspirations: a useful marker in the diagnosis of carcinoma. Mod Pathol 1997, 10: 668–74.PubMedGoogle Scholar
  22. 22.
    De Micco C, Zoro P, Garcia S, et al. Thyroid peroxidase immunodetection as a tool to assist diagnosis of thyroid nodules on fine-needle aspiration biopsy. Eur J Endocrinol 1994, 131: 474–9.PubMedCrossRefGoogle Scholar
  23. 23.
    Christensen L, Blichert-Toft M, Brandt M, et al. Thyroper-oxidase (TPO) immunostaining of the solitary cold thyroid nodule. Clin Endocrinol (Oxf) 2000, 53: 161–9.CrossRefGoogle Scholar
  24. 24.
    Lloyd RV. Distinguishing benign from malignant thyroid lesions: galectin 3 as the latest candidate. Endocr Pathol 2001, 12: 255–7.PubMedGoogle Scholar
  25. 25.
    Barondes SH, Cooper DNW, Gitt MA, Leffler H. Galectins: structure and function of a large family of animal lectins. J Biol Chem 1994, 269: 20807–10.PubMedGoogle Scholar
  26. 26.
    Inohara H, Akahani S, Koths K, Raz A. Interactions between galectin-3 and Mac-2-binding protein mediate cell-cell adhesion. Cancer Res 1996, 56: 4530–4.PubMedGoogle Scholar
  27. 27.
    Sato S, Hughes RC. Regulation of secretion and surface expression of Mac-2, a galactoside-binding protein of mac-rophages. J Biol Chem 1994, 269: 4424–30.PubMedGoogle Scholar
  28. 28.
    Dagher SF, Wang JL, Patterson RJ. Identification of galectin-3 as a factor in pre-mRNA splicing. Proc Natl Acad Sci USA 1995, 92: 1213–7.PubMedCentralPubMedCrossRefGoogle Scholar
  29. 29.
    Yang RY, Liu FT. Galectins in cell growth and apoptosis. Cell Mol Life Sci 2003, 60: 267–76.PubMedCrossRefGoogle Scholar
  30. 30.
    Takenaka Y, Inohara H, Yoshii T, et al. Malignant transformation of thyroid follicular cells by galectin-3. Cancer Lett 2003, 195: 111–9.PubMedCrossRefGoogle Scholar
  31. 31.
    Raz A., Lotan R. Endogenous galactoside-binding lectins: a new class of functional tumor cell surface molecules related to metastasis. Cancer Metastasis Rev 1987, 6: 433–52.PubMedCrossRefGoogle Scholar
  32. 32.
    Xu XC, El-Naggar AK, Lotan R. Differential expression of galectin-1 and galectin-3 in thyroid tumors. Am J Pathol 1995, 147: 815–22.PubMedCentralPubMedGoogle Scholar
  33. 33.
    Fernandez PL, Merino MJ, Gomez M, et al. Galectin-3 and laminin expression in neoplastic and non-neoplastic thyroid tissue. J Pathol 1997, 181: 80–6.PubMedCrossRefGoogle Scholar
  34. 34.
    Orlandi F, Saggiorato E, Pivano G, et al. Galectin-3 is a presurgical marker of human thyroid carcinoma. Cancer Res 1998, 58: 3015–20.PubMedGoogle Scholar
  35. 35.
    Bartolazzi A, Gasbarri A, Papotti M, et al. Application of an immunodiagnostic method for improving preoperative diagnosis of nodular thyroid lesions. Lancet 2001, 357: 1644–50.PubMedCrossRefGoogle Scholar
  36. 36.
    Cvejic D, Savin S, Paunovic I, Tatic S, Havelka M, Sinadinovic J. Immunohistochemical localization of galectin-3 in malignant and benign human thyroid tissue. Anticancer Res 1998, 18: 2637–41.PubMedGoogle Scholar
  37. 37.
    Nascimento MC, Bisi H, Alves VA, Longatto-Filho A, Kanamura CT, Medeiros-Neto G. Differential reactivity for galectin-3 in Hurthle cell adenomas and carcinomas. Endocr Pathol 2001, 12: 275–9.PubMedGoogle Scholar
  38. 38.
    Martins L, Matsuo SE, Ebina KN, Kulcsar MA, Friguglietti CU, Kimura ET. Galectin-3 messenger ribonucleic acid and protein are expressed in benign thyroid tumors. J Clin Endocrinol Metab 2002, 87: 4806–10.PubMedCrossRefGoogle Scholar
  39. 39.
    Bartolazzi A, Papotti M, Orlandi F. Methodological considerations regarding the use of galectin-3 expression analysis in preoperative evaluation of thyroid nodules. J Clin Endocrinol Metab 2003, 88: 950.PubMedCrossRefGoogle Scholar
  40. 40.
    Herrmann ME, LiVolsi VA, Pasha TL, et al. Immunohisto-chemical expression of galectin-3 in benign and malignant thyroid lesions. Arch Pathol Lab Med 2002, 126: 710–3.PubMedGoogle Scholar
  41. 41.
    Kashima K, Yokoyama S, Daa T, Nakayama I, Nickerson PA, Noguchi S. Cytoplasmic biotin-like activity interferes with immunohistochemical analysis of thyroid lesions: a comparison of antigen retrieval methods. Mod Pathol 1997, 10: 515–9.PubMedGoogle Scholar
  42. 42.
    Niedziela M, Maceluch J, Korman E. Galectin-3 is not an universal marker of malignancy in thyroid nodular disease in children and adolescents. J Clin Endocrinol Metab 2002, 87: 4411–5.PubMedCrossRefGoogle Scholar
  43. 43.
    Bernet VJ, Anderson J, Vaishnav Y, et al. Determination of galectin-3 messenger ribonucleic acid overexpression in papillary thyroid cancer by quantitative reverse transcription-polymerase chain reaction. J Clin Endocrinol Metab 2002, 87: 4792–6.PubMedCrossRefGoogle Scholar
  44. 44.
    Takano T, Miyauchi A, Matsuzuka F, Yoshida H, Kuma K, Amino N. Ubiquitous expression of galectin-3 mRNA in benign and malignant thyroid tumors. Cancer Lett 2003, 199: 69–73.PubMedCrossRefGoogle Scholar
  45. 45.
    Suarez HG. Genetic alterations in human epithelial thyroid tumors. Clin Endocrinol (Oxf) 1998, 48: 531–46.CrossRefGoogle Scholar
  46. 46.
    Satta MA, Nanni S, Della Casa S, Pontecorvi A. Molecular biology of thyroid neoplasms. Rays 2000, 25: 151–61.PubMedGoogle Scholar
  47. 47.
    French CA, Alexander EK, Cibas ES, et al. Genetic and biological subgroups of low-stage follicular thyroid cancer. Am J Pathol 2003, 162: 1053–60.PubMedCentralPubMedCrossRefGoogle Scholar
  48. 48.
    Nikiforova MN, Lynch RA, Biddinger PW, et al. RAS point mutations and PAX8-PPAR gamma rearrangement in thyroid tumors: evidence for distinct molecular pathways in thyroid follicular carcinoma. J Clin Endocrinol Metab 2003, 88: 2318–26.PubMedCrossRefGoogle Scholar

Copyright information

© Italian Society of Endocrinology (SIE) 2004

Authors and Affiliations

  • E. Saggiorato
    • 1
  • S. Aversa
    • 2
  • D. Deandreis
    • 1
  • F. Arecco
    • 1
  • A. Mussa
    • 1
  • B. Puligheddu
    • 1
  • S. Cappia
    • 3
  • S. Conticello
    • 2
  • M. Papotti
    • 3
    • 4
  • F. Orlandi
    • 1
  1. 1.Section of Endocrinology, Department of Clinical and Biological SciencesUniversity of TurinOrbassano, TurinItaly
  2. 2.Division of Otorhinolaryngology, Department of Clinical and Biological SciencesUniversity of TurinTurinItaly
  3. 3.Division of PathologySan Luigi HospitalItaly
  4. 4.Department of Biomedical Sciences and Human OncologyUniversity of TurinTurinItaly

Personalised recommendations